Compare SLDB & AEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SLDB | AEVA |
|---|---|---|
| Founded | 2013 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 623.0M | 708.9M |
| IPO Year | 2017 | 2020 |
| Metric | SLDB | AEVA |
|---|---|---|
| Price | $6.43 | $8.81 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 5 |
| Target Price | $18.71 | ★ $24.80 |
| AVG Volume (30 Days) | 1.2M | ★ 1.8M |
| Earning Date | 11-04-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.97 | 10.53 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $8,094,000.00 | N/A |
| Revenue This Year | N/A | $73.43 |
| Revenue Next Year | N/A | $132.18 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.65 | $8.26 |
| 52 Week High | $11.45 | $31.30 |
| Indicator | SLDB | AEVA |
|---|---|---|
| Relative Strength Index (RSI) | 46.83 | 40.20 |
| Support Level | $6.25 | $9.44 |
| Resistance Level | $6.58 | $16.49 |
| Average True Range (ATR) | 0.50 | 1.01 |
| MACD | 0.02 | 0.06 |
| Stochastic Oscillator | 30.12 | 25.89 |
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.
Aeva Technologies Inc through its Frequency Modulated Continuous Wave (FMCW) sensing technology, designs a 4D LiDAR-on-chip that, along with its proprietary software applications, has the potential to enable the adoption of LiDAR across broad applications from automated driving to consumer electronics, consumer health, industrial automation, and security application. The 4D LiDAR sensors are designed to detect both velocity and position, supporting perception and decision-making in automated systems. The company operates in North America, EMEA, and Asia. The company's revenue consists of sales of perception solutions or sensing systems and non-recurring engineering services. Geographically, it derives the majority of its revenue from North America.